ARS Pharmaceuticals Inc (SPRY) reports robust revenue growth and plans for sales force expansion amidst challenges in prescriber workflows and market penetration.
The consensus estimate for Q4 2025 revenue is $25.58 million, and the earnings are expected to come in at -$0.44 per share. The full year 2025's revenue is expected to be $81.72 million and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results